Pfiz­er is ax­ing its neu­ro­sciences di­vi­sion, lay­ing off 300 and dis­card­ing new drugs

Pfiz­er is start­ing out 2018 by rip­ping up its ear­ly-, mid-stage and pre­clin­i­cal R&D op­er­a­tions fo­cused on neu­ro­sciences and lay­ing off hun­dreds of work­ers en­gaged …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER